A new blood test by Labcorp can predict a woman’s risk of developing preeclampsia in her first trimester, potentially improving prenatal care and outcomes for mothers and babies. Preeclampsia affects 1 in 25 U.S. pregnancies and poses a higher risk for Black women. However, some doctors question the test’s utility and effectiveness, as there is no evidence-based intervention to prevent or reduce the impact of the disease. The test measures four biomarkers associated with preeclampsia risk and has up to 90% sensitivity and specificity. Costing about $240, the test is currently being discussed with health insurers for coverage.
Source link
New blood test could help spot preeclampsia in first trimester
